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Idarucizumab is a monoclonal antibody fragment speciﬁcally targeted to dabigatran. It has demonstrated
prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies
of young, elderly, and renally impaired volunteers. Although elective invasive procedures and most
bleeding complications in dabigatran-treated patients can be managed by temporarily stopping dabigatran
therapy and using supportive measures, there are rare clinical situations that require urgent reversal of the
anticoagulant effect of dabigatran. The effectiveness and safety of 5 g of intravenous idarucizumab is being
investigated in a prospective, open-label, single-cohort study in patients with serious bleeding or in those
requiring an urgent procedure. In an interim analysis of the ﬁrst 90 participants, idarucizumab rapidly and
completely reversed the anticoagulant activity of dabigatran in 88%-98% of participants, and there were no
safety concerns, with no deaths or serious adverse events being attributable to idarucizumab. Supported by
these interim results, idarucizumab has been approved in the United States and the European Union for use
when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures
or in patients with life-threatening or uncontrolled bleeding. Clinical use of idarucizumab should follow the
same processes as patient enrollment in this study, which is projected to be completed in 2016. The out-
comes achieved with this speciﬁc reversal agent are likely to be of continued interest to treating physicians.
 2016 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2016) 129, S73-S79
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Patients treated with dabigatran have normal synthesis and
levels of thrombin, but competitive inhibition of thrombin
activity by dabigatran effectively prevents completion of the
coagulation process. This mechanism of action has been
harnessed to provide effective anticoagulation in patients
with nonvalvular atrial ﬁbrillation (NVAF) to reduce the
risk of ischemic stroke and systemic embolization, and in
patients with or at risk of venous thromboembolic disease.1
In clinical trials, dabigatran has been associated with
similar or reduced rates of the key safety end points of major
and intracranial bleeding, depending on the dose and the
indication, as well as similar rates of fatal bleeding compared
with vitamin K antagonists (VKAs), such as warfarin.2-4
Nonetheless, some risk of bleeding unavoidably accom-
panies the decision to use an anticoagulant in a patient,
especially older patients with the comorbidities that typically
accompany NVAF. Most bleeding complications associated
with the use of dabigatran are minor or at worst moderate in-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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holding the drug and supporting the patient with general
physical or pharmacologic hemostatic measures, replacement
of shed blood, and observation.5,6 The short half-life of
dabigatran relative to VKAs, which inhibit the synthesis of
multiple coagulation factors over days, is an important
consideration in these strategies.1,7 Typically, the effect of
dabigatran—in the absence of acute renal failure or acute
overdose—dissipates within 12 hours of a 150-mg dose, with
steady-state dabigatran plasma concentrations decreasing to
<100 ng/mL and activated partial thromboplastin time to
approximately 1.5 times baseline levels in that interval.8,9
Similarly, the short half-life of dabigatran facilitates the
timing of elective invasive procedures. Withholding
the drug for 1-5 days, depending on renal status and the
magnitude of the bleeding risk associated with the proce-
dure, allows the intervention to be accomplished with
restored hemostasis.1 Because the onset of action of
dabigatran is—like its offset—rapid,10 re-initiation of anti-
coagulation can generally be accomplished as soon as
postprocedural hemostasis is restored.
In rare clinical situations, these general measures are
insufﬁcient to address bleeding complications or bleeding
concerns in patients requiring emergent invasive procedures
in the context of anticoagulation with dabigatran. In cases of
uncontrolled or life-threatening hemorrhage or when an
invasive procedure cannot be delayed long enough for nat-
ural decay of the anticoagulant effect of dabigatran, more
deﬁnitive reversal of anticoagulation is desirable. If dabi-
gatran was ingested within the preceding 2-3 hours, oral
administration of activated charcoal may limit absorption of
the most recent dose.8,11,12 Elimination of dabigatran—
which is 80% renal—can be maintained by vigorous ﬂuid
administration and resulting diuresis.1,5,8 However, these
approaches are of limited impact in most emergency situa-
tions. Unlike the other DOACs, dabigatran can be removed
rather effectively from the circulation by hemodialysis,
although data supporting this approach are limited.1,13,14
Unfortunately, this is a cumbersome and logistically chal-
lenging approach in the emergency situation, in patients
without established dialysis access.
Such patients, therefore, require urgent reversal of the
anticoagulant effect of dabigatran (ie, normalization of
thrombin activity in the presence of an effective
antithrombin agent). It is not possible to administer pure
thrombin to patients to overcome the competitive blockade
of dabigatran. Exogenous thrombin can be given in com-
bination with other coagulation factors using fresh frozen
plasma or 3- or 4-factor prothrombin complex concen-
trates.12 However, because levels of thrombin and other
coagulation factors are presumably normal in dabigatran-
treated patients, this approach introduces a concern for
iatrogenic creation of a hypercoagulable or prothrombotic
state, as has been demonstrated in an animal study,15
potentially trading one worrisome situation for another.
The preferred approach in such situations, therefore,
would be to use a speciﬁc reversal agent to remove theanticoagulant effect of dabigatran, disinhibiting native
thrombin and returning the patient to his or her baseline
coagulation status. An ideal reversal agent would be speciﬁc
to the administered anticoagulant, engage in no other
drugedrug interactions, have no inherent pro- or anticoag-
ulant effect, have rapid and predictable onset of action, be
readily prepared and administered, and be dosed in a simple
fashion. Additionally, it should have a sufﬁciently durable
effect that in cases of bleeding, coagulation can be main-
tained while deﬁnitive source management is being
accomplished, and in preprocedural patients, the procedure
can be completed without the additional bleeding risk
wrought by anticoagulation.
Idarucizumab meets these criteria for patients treated
with dabigatran who require immediate anticoagulation
reversal.16 Idarucizumab is a humanized monoclonal anti-
body fragment speciﬁcally directed at dabigatran.17
The active site of idarucizumab is structurally similar to
the dabigatran binding site of thrombin, although the anti-
body lacks enzymatic activity. Idarucizumab binds dabiga-
tran with approximately 350 times the avidity with which
thrombin binds dabigatran. As such, in sufﬁcient doses,
idarucizumab readily displaces dabigatran from thrombin
and tightly binds it, thereby allowing ﬁbrin formation to
ensue normally. The antibody can bind free and thrombin-
bound dabigatran, as well as extravascular dabigatran, as
it enters the central compartment after changes in the con-
centration gradient,18 thus preventing the anticoagulant from
the periphery from subsequent binding to thrombin.
The interaction between idarucizumab and dabigatran is
characterized by an extraordinarily rapid on rate (measured in
milliseconds) and a very slow off rate, consistent with the
high-afﬁnity binding typical of an antibodyeantigen bond.17
Binding is effectively irreversible, with very little dissociation
of the idarucizumabedabigatran complex before renal
excretion, even in patients with renal compromise.16-18When
infused intravenously, peak plasma concentrations of
idarucizumab are achieved almost immediately, allowing
prompt binding to dabigatran.19 The key clinical ﬁndings
from volunteer studies of idarucizumab are reviewed in detail
in the review article by Reilly et al. within this special issue
and are summarized in Table.20
Animal studies of idarucizumab likewise showed a prompt
and durable reversal of the anticoagulant effects of dabiga-
tran, without prothrombotic effect.17,23 In addition, phase I
studies showed only a low level of antibody formation after
single or repeat exposure to idarucizumab.16,18,19 No severe
or serious drug-related adverse events were identi-
ﬁed.16,18,19,22 The only side effect was a transient, dose-
related increase in urinary protein levels, which was to be
expected from the excretion of the antigeneantibody com-
plexes via a saturable renal protein transporter.19RE-VERSE AD, A STUDY IN PATIENTS
From all indications, then, idarucizumab seemed to be a
promising speciﬁc reversal agent for dabigatran. A clinical
Table Key Clinical Phase 1 Findings with Idarucizumab in Healthy Volunteers
Objective No. of Subjects Findings
Reversal of anticoagulant effect of dabigatran in
healthy young (age 18-64 y) volunteers
59 Dose-dependent decrease in ECT, dTT, aPTT, TT,
and ACT
Reversal of anticoagulant effect of dabigatran in
elderly (age 65-80 y) volunteers
16 Dose-dependent decrease in ECT, dTT, aPTT, TT,
and ACT
Reversal of anticoagulant effect of dabigatran in
subjects with creatinine clearance 44e79 mL/min
18 Dose-dependent decrease in ECT, dTT, aPTT, TT,
and ACT
Pharmacokinetics of idarucizumab alone in
healthy volunteers
110 Initial t1/2 w45 minutes
Pharmacokinetics of dabigatran in volunteers
given idarucizumab
93 Unbound dabigatran concentrations determined
using HPLC/MS parallel results of clotting tests
Re-initiation of dabigatran 24 h after
idarucizumab administration
12 Full anticoagulant effect of dabigatran 24 h after
idarucizumab administration
Re-exposure to idarucizumab 2 mo after initial
administration
6 No hypersensitivity, 1 subject developed new
anti-drug antibodies
Evaluation of potential procoagulant activity of
idarucizumab
104 No increase in thrombin generation compared
with placebo
Safety of idarucizumab 203 No dose-related adverse events, no serious
adverse events
See references.19,22
ACT ¼ activated clotting time; aPTT ¼ activated partial thromboplastin time; dTT ¼ dilute thrombin time; ECT ¼ ecarin clotting time;
HPLC/MS ¼ high-performance liquid chromatography/tandem mass spectrometry.
Reproduced with permission from Pollack et al.21
Pollack Idarucizumab for Dabigatran Reversal S75study in patients to support registration was developed with
input from various regulatory bodies, and ultimately the
following key decisions were made concerning the design of
this study of idarucizumab. An open-label, single-cohort
design was selected. Although it was of course recognized,
that a blinded, controlled study would represent better
“science,” this approach was not deemed feasible or
appropriate for a study of idarucizumab. Blinded, placebo-
controlled studies had already been conducted in healthy
volunteers, demonstrating safety and efﬁcacy according to
reversal of clotting tests. The drug seemed to be so effective
in these studies that it was not thought ethical to enroll a
placebo-treated group. In addition, such a controlled study,
with clinical outcomes as the primary end point, would
require thousands of patients and could take 5-10 years to
complete owing to the difﬁculties of ﬁnding, consenting,
and treating eligible dabigatran-treated patients as soon as
they appeared in emergency departments. Likewise, there
seemed to be no rational comparator control, because there
is no standard treatment for dabigatran-associated bleeding,
and no studies have evaluated the effects of other reversal or
repletion strategies for dabigatran that could represent a
“gold standard” alternative to idarucizumab.21
Purely clinical inclusion criteria were selected because
worldwide there are no readily available coagulation tests to
evaluate the magnitude of dabigatran-associated anti-
coagulation. Meanwhile, the use of time-consuming,
experimental tests or qualitative tests before enrollment
was not deemed to be in the patient’s best interest. The
protocol was instead written to allow full discretion by the
local investigator to make the clinical decision thatimmediate reversal of anticoagulation was warranted—
whether in the management of hemorrhage or the prevention
of procedural bleeding—and that open-label idarucizumab
should be administered.21
Two groups of dabigatran-treated patients were also
selected because oral anticoagulation may occasionally
result in 2 separate and distinct clinical challenges: man-
agement of hemorrhage abetted by the iatrogenic coagul-
opathy (enrolled as “group A”) and management of
anticoagulated patients who are not bleeding but who
require urgent or emergent invasive procedures (“group B”)
that (1) cannot be safely postponed (for at least 8 hours) and
(2) cannot be safely performed without baseline restoration
of hemostasis. It was further decided not to impose clinical
limits on the trial population so that it represented as best as
possible the types of patients who would likely be given
idarucizumab in “real-world” situations. The following
patients were, therefore, eligible for inclusion in the trial:
those with intracranial hemorrhages, with high expected
mortality, those with other life-threatening conditions
(eg, sepsis, multiple trauma with hemorrhagic shock), and
those who had received other reversal/repletion therapies. In
addition, measures to control bleeding in patients in group A
were permitted during the trial. These could include
mechanical and supportive measures, decontamination
procedures (eg, activated charcoal or dialysis), factor
repletion, or the administration of other hemostatic agents
(eg, tranexamic acid).21
The primary efﬁcacy end point for the study was based
on laboratory assessments of coagulation, not clinical
outcomes. The types of patients represented in the 2 study
S76 The American Journal of Medicine, Vol 129, No 11A, November 2016groups—bleeding and preprocedural—are quite heteroge-
neous in terms of presentation, source of bleeding or type of
procedure needed, comorbidity burden, age, and indication
for anticoagulation. Therefore, meaningful clinical end
points could not be used to establish a sample size for the
study. Additionally, idarucizumab is a speciﬁc reversal
agent; that is, it is to be used when reversal of dabigatran-
associated anticoagulation is deemed clinically necessary.
However, successful reversal of anticoagulation in a hem-
orrhaging patient does not necessarily result in cessation of
bleeding. Therefore, the best measure of reversal is the
central laboratory assessment of coagulation parameters
known to correlate with dabigatran concentrations. In fact, 2
coagulation assays—the dilute thrombin time (dTT) and the
ecarin clotting time (ECT) can be used in this way.10,24
Therefore, although numerous clinical outcomes were to
be collected and reported in the study, the primary end point
would be coagulation testing performed by a central labo-
ratory that was geographically and temporally separated
from patient care. These tests were supplemented by also
directly measuring the amount of total and unbound dabi-
gatran as a secondary end point, to conﬁrm that the effects
on clotting tests reﬂected the binding/elimination of dabi-
gatran and were not artifacts of the patients’ conditions.
The resulting “real-world” evaluation of idarucizumabwas
called the study of the REVERSal Effects of Idarucizumab in
Patients on Active Dabigatran (RE-VERSE AD) and is an
ongoing, global, phase 3 prospective, single-cohort study
aimed at investigating idarucizumab in dabigatran-treated
patients who present with uncontrollable or life-threatening
bleeding, and in those requiring urgent surgery or interven-
tion.25 The study is being pursued in more than 400 sites in
nearly 40 countries and ultimately will enroll 500 patients.
The originally planned sample size of 200-300 patients was
increased to 500 as part of postapproval requirements by the
U.S. Food and Drug Administration (FDA).25,26
The ﬁrst patient was enrolled in June 2014, and interim
results from the ﬁrst 90 enrollees were presented at the
International Society of Thrombosis and Haemostasis
congress and published in the New England Journal of
Medicine in June 2015.25,27 Idarucizumab was subsequently
approved as Praxbind by the FDA in October 2015 and by
the European Medicines Agency in November 2015.28,29
All patients in RE-VERSE AD receive 5 g idarucizumab
administered as 2 successive intravenous infusions of
2.5-g vials, each given as a rapid infusion, no more than
15 minutes apart.25 The only requirement for care between
the 2 infusions is a blood draw for coagulation analysis; this
would not be considered a necessary step in clinical prac-
tice. The primary end point is the maximum percentage
reversal of the anticoagulant effect of dabigatran within
4 hours of completion of idarucizumab dosing, as assessed
by central laboratory measurement of the dTT or ECT.
Key clinical end points include time to cessation of bleeding
in group A patients and assessment of hemostasis during
interventions in group B patients. An interim analysis of the
ﬁrst 90 patients enrolled (51 in group A, 39 in group B)revealed that most (>90%) were receiving dabigatran for
stroke prevention in the setting of NVAF and, accordingly,
were elderly (median age: 76.5 years) and had a typical age-
appropriate comorbidity burden, including some degree of
renal insufﬁciency.
In keeping with the “all-comers” approach to establishing
eligibility for idarucizumab to reverse dabigatran-associated
anticoagulation, 16 of the 51 group A patients were hemo-
dynamically unstable at enrollment, and 18 had intracranial
hemorrhage. In group B, the most common indications for
emergency surgery were open bone fractures and acute
abdomen. The median patient-reported time since the last
dose of dabigatran was 15.2 and 16.6 hours in groups A and
B, respectively, although this time included initial evalua-
tion after arrival at the site of care.25
Overall, 68 (76%) and 81 (90%) of the 90 patients had an
elevated dTT or ECT at study entry as determined by central
laboratory analysis. Normal dTTs were found in 11 of 51
patients in group A and in 11 of 39 patients in group B, and
normal ECTs in 4 and 5 patients in the respective groups.
It should be kept in mind that treating clinicians did not have
access to these results in “real time” and that all enrollment
criteria were clinical, based on a bedside evaluation that
immediate reversal was warranted.25
The efﬁcacy analysis included only those patients with
elevated clotting test results at baseline. After administration
of 5-g idarucizumab, the median maximum percentage
reversal in dTT or ECT within 4 hours in eligible patients
was 100% (95% conﬁdence interval, 100%-100%), and
reversal was evident immediately after the ﬁrst vial of idar-
ucizumab was given. Idarucizumab normalized dTT in 98%
(group A) and 93% (group B) and ECT in 89% (group A) and
88% (group B) of eligible patients (Figure 1).25
Plasma concentrations of unbound dabigatran were
reduced to at or near the lower limit of quantiﬁcation in all
but 1 patient immediately after idarucizumab administration.
At 24 hours, 79% of patients had plasma concentrations of
active (unbound) dabigatran that were <20 ng/mL, a level
associated with little or no anticoagulant activity.9 The
subsequent increases in dabigatran concentrations observed
in 6 and 16 patients, at 12 and 24 hours after idarucizumab
administration, respectively, were accompanied by increases
in clotting times. This response is most likely attributable to
the redistribution of extravascular dabigatran into the
intravascular compartment. If these elevations in clotting
tests are associated with rebleeding, a second 5-g dose of
idarucizumab may be considered in such patients, although
the safety and effectiveness of a second dose has yet to be
established.16
In the 51 patients in group A, time to bleeding cessation
could be determined in 38 patients (13 patients had bleeding
at sites not readily accessible). The investigator-reported
median time to cessation of bleeding was 11.4 hours, but
this information is highly variable and was not guided by
any speciﬁc evaluation schedule or deﬁnition. In group B,
normal intraoperative hemostasis was reported in 92% of the
36 patients who underwent procedures after reversal.25
Figure 1 Time course of the dilute thrombin time and ecarin clotting time before and after the
administration of idarucizumab. Reprinted with permission of Massachusetts Medical Society from
Pollack et al.25 The analyses included 51 patients who had serious bleeding (group A; A and C) and 39
who required urgent surgery or intervention (group B; B and D). Idarucizumab was administered in 2
infusions. Blood samples were obtained at baseline, after the ﬁrst infusion, at 10-30 minutes after the
administration of the second infusion, and at 1, 2, 4, 12, and 24 hours. Data are presented as box-and-
whisker plots, in which the top and bottom of the rectangles indicate the 75th and 25th percentiles,
respectively; the horizontal lines within the rectangles indicate the 50th percentile; the lines above and
below the rectangles indicate the 90th and 10th percentiles, respectively; and the dots above and below
the lines indicate the 95th and 5th percentiles, respectively. The dashed lines indicate the upper limit of
the normal range for the tests.
Pollack Idarucizumab for Dabigatran Reversal S77The median time between administration of idarucizumab
and the start of the procedure was 1.7 hours, and no post-
surgical bleeding complications were reported in the 24
hours after surgery for any of the 36 procedural patients.30
Thromboembolic events (including deep vein throm-
bosis, pulmonary embolism, myocardial infarction, orischemic stroke) occurred in 5 of the 90 patients in the
interim analysis: 1 occurring within 48 hours of idar-
ucizumab administration, and 4 more than 72 hours after
dosing. It is signiﬁcant that at the time of the complication,
none of these 5 patients had been re-initiated on any
antithrombotic therapy after reversal of anticoagulation.
S78 The American Journal of Medicine, Vol 129, No 11A, November 2016Among these 90 patients, 18 (9 in each group) died during
the 90-day follow-up period. The 9 deaths that occurred
within 96 hours after reversal reﬂected the disease process
or injury that prompted the need for reversal, whereas the 9
deaths that occurred later were related to pre-existing
medical conditions. No deaths and no serious adverse
events were attributable to idarucizumab.25
Most patients had anticoagulation therapy re-initiated
after reversal.25 The time to restart varied, with a longer time
for patients in group A who had experienced life-threatening
bleeding events than for surgical patients in group B for
whom hemostasis was more clearly established before
re-initiation (median time: 4.1 vs 1.4 days, respectively).31
Approximately half of the patients who restarted on dabiga-
tran were given an injectable anticoagulant ﬁrst.31 In patients
with renal impairment, the half-lives of both dabigatran and
idarucizumab are prolonged.1,16 No adjustment of timing of
re-initiation of dabigatran is necessary in these patients.
The interim results supported the rapid approval of
idarucizumab by both the FDA and the European Medicines
Agency. The target population mirrored the inclusion
criteria and administration used in RE-VERSE AD.
The study will be complete in 2016 after the enrollment ofFigure 2 Management of bleeding in patients takin
therapeutic measures in case of minor or severe bleed
Ryn et al.8 Adapted with permission of Oxford Uni
activated prothrombin complex concentrate; IV ¼ in
PCC ¼ prothrombin complex concentrate; RBC ¼ r
count.500 patients worldwide.25 Clinical use of idarucizumab will
ensue in parallel to study enrollment, and there will doubt-
less be varying protocols governing access to the reversal
agent in the emergency care setting.CONCLUSIONS
Use of idarucizumab will be unusual in the clinical setting if
it is used per label and as it is being used in RE-VERSE AD:
only in those situations in which emergency reversal is
clinically warranted. Most DOAC-related bleeding does not
require reversal; most invasive procedures in anticoagulated
patients can be safely delayed until the anticoagulant effect
has diminished. The exceptions—true surgical emergencies,
intracranial hemorrhage, exsanguinating gastrointestinal
bleeds, multiple trauma with hemorrhagic shock—are dra-
matic but rare. The usual measures to support and stabilize
dabigatran-treated patients with controllable hemorrhage of
bleeding concerns should still be followed, reserving idar-
ucizumab for refractory cases (Figure 2).
Further clinical experience will be required to determine
the frequency of a need for repeated doses of idarucizumab.
Given the overwhelming nature of the 5-g dose (with respectg direct oral anticoagulants (DOACs). Possible
ing in patients on DOAC therapy. Based on van
versity Press from Heidbuchel et al.5 aPCC ¼
travenous; NOAC ¼ novel oral anticoagulant;
ed blood cell count; WBC ¼ white blood cell
Pollack Idarucizumab for Dabigatran Reversal S79to dabigatran levels measured in the Randomized Evaluation
of Long-term anticoagulation therapY [RE-LY] trial), this
should be unusual and should be considered only when
pathologic bleeding persists or recurs after initial reversal, or
if a second urgent/emergent procedure is required and
clotting studies suggest a recurrent dabigatran effect. It is
anticipated that there will be broad and deep interest in the
clinical use of the drug and the outcomes achieved.
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